Fibrodysplasia ossificans progressiva: A blueprint for metamorphosis

Annals of the New York Academy of Sciences

Volumn 1237, Issue 1, 2011, Pages 5-10

  Kaplan, Frederick S ^a   Lounev, Vitali Y ^a   Wang, Haitao ^a   Pignolo, Robert J ^a   Shore, Eileen M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ACVR1; ALK2; BMP; Fibrodysplasia; Heterotopic ossification; Ossificans progressiva

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN;

ARTICLE; CELL FATE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HYPOXIA; INFLAMMATION; MESENCHYMAL STEM CELL; METAMORPHOSIS; NONHUMAN; OSSIFYING MYOSITIS; RECEPTOR BLOCKING;

EID: 81255197446     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06195.x     Document Type: Article

References (40)

1. Shore, E.M. et al 2006. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. 38: 525-527.
2. Kaplan, F.S. et al 2009. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum. Mutat. 30: 379-390.
3. Shen, Q. et al 2009. Fibrodysplasia ossificans progressiva ACVR1 (R206H) mutation activates BMP-independent chondrogenesis and ventralization of zebrafish embryos. J. Clin. Invest. 119: 3462-3472.
4. Fukada, T. et al 2009. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J. Biol. Chem. 284: 7149-7156.
5. Song, G.-A. et al 2010. Molecular consequences of the ACVR1 R206H mutation of fibrodysplasia ossificans progressiva. J. Biol. Chem. 285: 22542-22553.
6. Van Dinther, M. et al 2010. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J. Bone Miner. Res. 25: 1208-1215.
7. Kaplan, F.S. et al 2005. The phenotype of fibrodysplasia ossificans progressiva. Clin. Rev. Bone & Miner. Metab. 3: 183-188.
8. Kaplan, F.S. & E.M. Shore 2007. Morphogen receptor genes and metamorphogenes: skeleton keys to metamorphosis. Ann. N.Y. Acad. Sci. 1116: 113-133.
9. Kaplan, F.S. et al 2008. Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). J. Bone Miner. Metab. 26: 521-530.
10. Kaplan, F.S. et al 2009. The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine Growth Factor Rev. 20: 399-407.
11. Shore, E.M. & F.S. Kaplan 2010. Inherited human diseases of heterotopic bone formation. Nat. Rev. Rheumatol. 6: 518-527.
12. Kaplan, F.S. et al 2010. Fibrodysplasia ossificans progressiva: developmental implications of a novel metamorphogene. In Bone and Development. (Chapter 14). Bronner, Farach-Carson & Roach, Eds.: 233-249. Springer-Verlag. London
13. Gazzerro, E. & E. Canalis 2006. Bone morphogenetic proteins and their antagonists. Rev. Endocr. Metab. Disord. 7: 51-65.
14. Derynck, R. & R. J. Akhurst 2007. Differentiation plasticity regulated by the TGF-β family proteins in development and disease. Nat. Cell Biol. 9: 1000-1004.
15. Sieber, C. et al 2009. Recent advances in BMP receptor signaling. Cytokine & Growth Factor Rev. 20: 343-355.
16. Song, B. et al 2009. Smad signaling in skeletal development and regeneration. Cytokine & Growth Factor Rev. 20: 379-388.
17. Kaplan, F.S. et al 1993. The histopathology of fibrodysplasia ossificans progressiva: an endochondral process. J. Bone Joint Surg. Am. 75: 220-230.
18. Gannon, F.H. et al 1998. Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 346: 19-25.
19. Gannon F.H. et al 2001. Mast cell involvement in fibrodysplasia ossificans progressiva. Hum. Pathol. 32: 842-848.
20. Kaplan, F.S. et al 2005. Immunological features of fibrodysplasia ossificans progressiva (FOP) and the dysregulated BMP4 pathway. Clin. Rev. Bone Miner. Metab. 3: 189-193.
21. Glaser, D.L. et al 2003. In vivosomatic cell gene transfer of an engineered noggin mutein prevents BMP4-induced heterotopic ossification. J. Bone Joint Surg. 85-A: 2332-2342.
22. Hegyi, L. et al 2003. Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification. J. Pathol. 201: 141-148.
23. Stoick-Cooper, C.L. 2007. Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine. Genes & Development 21: 1292-1315.
24. Kaplan, F.S. et al 2007. Hematopoietic stem-cell contribution to ectopic skeletogenesis. J. Bone Joint Surg. Am. 89: 347-357.
25. Kan, L. et al 2004. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am. J. Pathol. 165: 1107-1115.
26. Kan, L. et al 2009. Dysregulation of local stem/progenitor cells as a common cellular mechanism for heterotopic ossification. Stem Cells 27:150-156.
27. Yu, P.B. et al 2008. BMP type I receptor inhibition prevents ectopic ossification in mouse model of fibrodysplasia ossificans progressiva (FOP). Nat. Med. 14: 1363-1369.
28. Lounev, V.Y. et al 2009. Identification of progenitor cells that contribute to heterotopic skeletogenesis. J. Bone Joint Surgery Am. 91: 652-663.
29. Eltzschig, H.K. & P. Carmeliet 2011. Hypoxia and inflammation. N. Engl. J. Med. 364: 656-665.
30. Olmsted-Davis, E. et al 2007. Hypoxic adipocytes pattern early heterotopic bone formation. Am. J. Pathol. 170: 620-632.
31. Wang, H. et al 2008. Hypoxia promotes ligand-independent activation of the ACVR1 (R206H) mutant receptor in C2C12 cells. J. Bone Miner. Res. 23: s433.
32. Billings, P.C. et al 2008. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva. J. Bone Miner. Res. 23: 305-313.
33. Medici, D. et al 2010. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat. Med. 12: 1400-1406.
34. Suda, R.K. et al 2009. Circulating osteogenic precursor cells in heterotopic bone. Stem Cells 27: 2209-2219.
35. Kaplan, F.S. et al 2008. Fibrodysplasia ossificans progressiva. Best Pract. Res. Clin. Rheumatol. 22: 191-205.
36. Kaplan, F.S. et al 2009. When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva. Drug Disc. Today: Therapeutic Strategies 5: 255-262.
37. Hong, C.C. & P.B. Yu 2009. Applications of small molecule BMP inhibitors in physiology and disease. Cytokine & Growth Factor Rev. 20: 409-418.
38. Shimono, K. et al 2011. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor γ agonists. Nat. Med. 17: 454-460.
39. Kaplan, F.S. & E.M. Shore 2011. Derailing heterotopic ossification and RARing to go. Nat. Med. 217: 420-421.
40. Brooks, D. Tools for thinking. New York Times March 28, 2011.